Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Preferred Stock Liabilities (2018)

Historic Preferred Stock Liabilities for Exagen (XGN) over the last 1 years, with Q4 2018 value amounting to $105.2 million.

  • Exagen's Preferred Stock Liabilities changed N/A to $105.2 million in Q4 2018 from the same period last year, while for Dec 2018 it was $105.2 million, marking a year-over-year change of. This contributed to the annual value of $105.2 million for FY2018, which is N/A changed from last year.
  • Latest data reveals that Exagen reported Preferred Stock Liabilities of $105.2 million as of Q4 2018.
  • Exagen's Preferred Stock Liabilities' 5-year high stood at $105.2 million during Q4 2018, with a 5-year trough of $105.2 million in Q4 2018.